Cormorant Asset Management filed to raise a new $400 million healthcare fund, underscoring renewed venture appetite for later‑stage biotech and life sciences investments. The Boston investor began fundraising this month and is positioning the vehicle to back growth‑stage companies and platform plays. In Asia, Phrontline Biopharma Suzhou closed a $60 million pre‑A+ round to advance its bispecific ADC programs, led by Lapam Investment and supported by strategic investors including Samsung Venture Investment. The capital will finance preclinical and IND‑enabling activities for next‑generation ADC candidates. These financings reflect regional and sectoral deal activity: large institutional funds seek diversified biotech exposure while emerging biotech hubs continue to attract targeted venture capital for modality platforms such as ADCs.